ctx130
crispr therapeutics ag
['advance', 'manta']
sumanta pal ( ) from shares phase i safety results for a car t cell trial in #ccrcc at #sitc22. to read more about #io and #act advances for renal cell carcinoma, check out this #jitc article: 